Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace)
What studies of Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, the placebo trial (very low certainty): 5 of 6 findings are D.
6 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Anxiety1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out.
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
No clear difference in anxiety.
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on anxiety in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- diary anxiety
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Depression1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out.
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
No clear difference in depression.
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on depression in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- PHQ9 (between-group difference) Patient Health Questionnaire
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Low mood or anxiety1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out.
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
No clear difference in low mood or anxiety.
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on low mood or anxiety in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- diary mood
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Sleep1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out.
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
No clear difference in sleep.
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on sleep in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- PSQI (between-group difference) Pittsburgh Sleep Quality Index
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Fatigue1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Worse F
Why this grade: Worse, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all).
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
Fatigue was worse with cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace).
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on fatigue in long COVID. Worse · very low certainty F
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- FAS (between-group difference) Fatigue Assessment Scale
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning1 study · 20 people received Cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out.
The placebo trial40 analysed · 3 weeks · 100 μA, 60 min daily for 3 weeks
No clear difference in daily functioning.
The evidence is very uncertain about the effect of cranial electrotherapy (CES: Alpha-Stim, Fisher Wallace) on daily functioning in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 40 analysed
- Dose
- 100 μA, 60 min daily for 3 weeks
- Outcome
- diary physical limitations
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- Effects of Cranial Electrotherapy Stimulation in Patients with Post-COVID-19 Condition on Anxiety Symptoms: A Randomised Controlled Trial.2025 · placebo trial · 40 analysed
Summary
People with post-COVID-19 condition (PCC) admitted to a 3-week comprehensive rehabilitation at Schoen Klinik Berchtesgadener Land, Germany, were randomised to rehabilitation plus cranial electrotherapy stimulation (CES, 100 μA via electrodes to the earlobes for 60 min daily for 3 weeks) or rehabilitation plus sham stimulation with identical devices that did not apply any electricity for 60 min/day. Forty people completed the trial (20 in each group). The primary outcome was change in anxiety symptoms on the Beck Anxiety Inventory (BAI) from baseline to post-rehab, with PHQ9, Fatigue Assessment Scale (FAS), Pittsburgh Sleep Quality Index (PSQI), daily diary ratings and comfort/efficiency ratings also collected. Both groups improved significantly on the BAI (CES p = 0.037; sham p = 0.018), with no between-group difference (p = 0.82). In an anxious subgroup (10 per group), BAI improved in both groups (p = 0.008; p = 0.002) with no between-group difference (p = 0.69). PHQ9 improved in both groups; only the sham group reached significant FAS improvement (between-group p = 0.048 in favour of sham); only the CES group showed significant PSQI improvement (between-group p = 0.25). Diary anxiety, mood and physical limitations showed no significant between-group differences; fatigue (p = 0.027) and sleep quality (p = 0.034) at discharge differed in favour of sham. There were no adverse events in either group during rehab. Six patients dropped out (2 intolerance to ear clips, 1 rehospitalisation, 3 non-compliance). The authors state limits including no sample size calculation and varying anxiety levels including subclinical symptoms.
- Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
Summary
This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.
- Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
Summary
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
- Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
Summary
This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.